1. At a Glance – The Hospital That Replaces Knees Faster Than It Replaces Profits
Market Cap: ₹1,693 Cr.
Current Price: ₹157
Stock P/E: 210
ROCE: 6.12%
ROE: 0.62%
Debt: ₹535 Cr
Q3 FY26 Revenue: ₹272 Cr
Q3 FY26 PAT: ₹1.28 Cr
Ladies and gentlemen, welcome to Shalby Ltd — the self-proclaimed global leader in knee replacements but currently limping in the profit department.
Revenue for Q3 FY26 stood at ₹272 Cr (down YoY marginally), while PAT collapsed to just ₹1.28 Cr. Yes, ₹1.28 Cr. That’s smaller than the monthly EMI of some Bollywood mansions.
Meanwhile, the stock trades at a P/E of 210. Two hundred and ten. For a company generating ₹0.16 EPS this quarter.
Return over 3 months? -29.8%.
Return over 1 year? -22.5%.
So the big question is:
Are we looking at a temporarily sedated patient… or a hospital chain that needs its own ICU admission?
Let’s scrub in.
2. Introduction – From 6 Beds to 2,300+ Beds (But Where’s the Profit?)
Shalby started in 1994 as a 6-bed hospital in Ahmedabad. Today it has:
- 15 hospitals
- 2,300+ beds
- 60 domestic OPDs
- 23 international OPDs
- 1,75,000+ joint replacement surgeries
That’s a solid legacy.
But markets don’t reward legacy. They reward cash flow.
Between FY22 and FY24, healthcare services revenue grew 28%. Implant revenue grew 150%. Sounds like a dream.
But then you open the FY25 numbers…
Revenue: ₹1,087 Cr
Net Profit: ₹2 Cr
Two. Crore.
And debt has jumped from ₹155 Cr in FY22 to ₹535 Cr now.
So the hospital expanded. The implants scaled. The surgeries increased.
But profit margin said: “Main chalta hoon.”
Is this growth with leverage? Or leverage without growth?
3. Business Model – WTF Do They Even Do?
Shalby runs two main businesses:
1️ Healthcare Services (90% of revenue in H1 FY25)
They operate:
- 11 multi-specialty hospitals
- 5 orthopaedic centers
- 2,350+ beds
- 30+ specialties
Core focus? Arthroplasty (joint replacements).
In Q3
